Validity of an Online Neurocognitive Test Battery, the Brain Performance Test (BPT), in Normal Healthy Adults

Overview

The purpose of this study is to evaluate the concurrent validity between the Brain Performance Test (BPT) subtests and corresponding conventional in-person neuropsychological assessments (NP).

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: Single (Participant)
  • Study Primary Completion Date: February 28, 2017

Detailed Description

This will be a multi-site, randomized, counterbalanced, two-period, two-sequence, validation study of the online, unsupervised Brain Performance Test (BPT). Over the course of 14 days, participants will complete two in-clinic visits during which they will complete both the BPT and in-person neuropsychological assessments (NP).

Interventions

  • Other: BPT
    • Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
  • Other: NP
    • Conventional in-person Neuropsychological Assessments (NP) Subtests from: HRB: Halstead-Reitan Battery MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia WAIS-IV: Weschler Adult Intelligence Scale – IV

Arms, Groups and Cohorts

  • Experimental: BPT, NP
    • Computerized assessment battery, followed by a 10 minute break, followed by conventional in-person neuropsychological assessments
  • Experimental: NP, BPT
    • Conventional in-person neuropsychological assessments, followed by a 10 minute break, followed by a computerized assessment battery

Clinical Trial Outcome Measures

Primary Measures

  • Correlation coefficients (Pearson’s r) of scaled scores of BPT subtests compared to scaled scores of their NP correlates at Time 1
    • Time Frame: 1 day

Secondary Measures

  • Interclass correlations (ICC) of scaled scores of BPT subtests compared to scaled scores of their NP correlates at Time 1
    • Time Frame: 1 day
  • Correlation coefficients (Pearson’s r and ICC) of raw scores of BPT subtests compared to raw scores of their NP correlates at Time 1
    • Time Frame: 1 day
  • Correlation coefficients (Pearson’s r and ICC) of BPT composite indices and NP composite indices at Time 1
    • Time Frame: 1 day
  • Correlation coefficients (Pearson’s r and ICC) of raw and scaled scores of BPT subtests at Time 1 and Time 2 as measures of test-retest reliability
    • Time Frame: 2 weeks
  • Correlation coefficients (Pearson’s r and ICC) of composite indices of BPT and NP at Time 1 and Time 2 as measures of reliability
    • Time Frame: 2 weeks
  • Correlation coefficients (Pearson’s r and ICC) of BPT Grand Index and NP Overall Index at Time 1 and Time 2 as measures of reliability
    • Time Frame: 2 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • Native English speaker – Capable and willing to provide informed consent – Able to use a computer and mouse without assistance – Limited (< 3 days) or no experience with Lumosity.com – Limited (< 3 days) or no experience with other cognitive training programs (e.g., FitBrains, CogMed) – Willing to refrain from online cognitive training during the course of the study – No recent (<1 years) experience with either computer-based or in-person neuropsychological tests (e.g., WAIS-IV, WISC, Halstead-Reitan Battery, MATRICS, CogState, CNS Vital Signs) – Good general health assessed via self-reported online physical questionnaire and medical history questionnaire Exclusion Criteria:

  • Illiterate or unable to understand written English sufficiently to comprehend study instructions and consent form – Uncorrected visual impairment (beyond that required to qualify for a California Driver's License) that may impact the ability to complete assessments (self-report or determined by the clinician) – Uncorrected auditory impairment that may impact the ability to complete assessments (self-report or determined by the clinician) – Self-reported clinical diagnosis for primary psychiatric or neurological disorder (e.g., schizophrenia, multiple sclerosis, attention deficit hyperactivity disorder, Parkinson's disease, epilepsy) – Self-reported history of concussion or traumatic brain injury, that is considered clinically significant in the opinion of the investigator (e.g. loss of consciousness ≤ 30 minutes) – Self-reported diagnosis of mental retardation or pervasive developmental disorder – Self-reported diagnosis of Mild Cognitive Impairment, Alzheimer's disease, or other dementia – Self-reported history of sustained substance or alcohol abuse or dependence, that is considered clinically significant in the opinion of the investigator (e.g. as defined by DSM-5) – Self-report that subject is currently taking an antipsychotic, antidepressant, anti-anxiety, or a cognitively-enhancing medication (e.g. Ritalin), or in the last 72 hours, narcotics for pain or other medications that may impact cognitive performance (e.g. sleeping medications/aides or cold/allergy medications) – Any other significant medical condition that could impact cognitive performance or result in cognitive impairment in the opinion of the investigator – Score <28 on the MMSE – Positive urine test for recent substance use on either testing day – Breath Alcohol Content of 0.01% or greater on either testing day

Gender Eligibility: All

Minimum Age: 70 Years

Maximum Age: 89 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Lumos Labs, Inc.
  • Collaborator
    • Collaborative Neuroscience Network
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • David Walling, PhD, Principal Investigator, Collaborative Neuroscience Network

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.